Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Person › Details

Jeffrey W. (Jeff) Albers (Blueprint Medicines Corporation (Nasdaq: BPMC))

Albers, Jeffrey W. (Jeff) (Blueprint Medicinces 201201– President of Algeta US + Genzyme + Mintz Levin)

 

Organisations Organisation Blueprint Medicines Corporation (Nasdaq: BPMC)
  Former/major organisation Algeta US LLC
  Group Bayer (Group)
Products Product kinase inhibitor
  Product 2 Xofigo® (Alpharadin™)
     

Algeta ASA. (1/17/12). "Press Release: Jeffrey W. Albers Appointed President of Algeta US". Oslo.

Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, is pleased to announce the appointment of Jeffrey W. Albers as President of Algeta US, the Company's new US commercial operation. He takes up his position immediately and will join Algeta's executive management team, reporting to President and CEO, Andrew Kay.

Mr. Albers will work closely with Algeta's senior management as part of the executive management team to enable Algeta's US commercial operations; the current plans for which include the phased building of a sales force and a marketing and medical affairs team ahead of the launch of Alpharadin (radium-223 chloride) for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases, pending approval. The US Food and Drug Administration granted Alpharadin Fast Track Designation, and commercial and regulatory activities are being undertaken for Alpharadin in anticipation of the first regulatory filings, which are expected in mid 2012.

In September 2009, Algeta entered into a licensing and development agreement with Bayer Pharma AG. Under the terms of the Bayer Agreement, Algeta has a right to co-promote Alpharadin in the United States for the prevention or treatment of disease.

Mr. Albers joins Algeta from Genzyme (Sanofi), where he spent the past seven years in senior commercial and corporate development positions, most recently as Vice President, US Hematology & Oncology Business. In this role, Mr. Albers had P&L responsibility for a USD 250m business that included multiple marketed products along with a pipeline of products to treat hematologic and solid tumor malignancies. He built and led a 135-person team spanning sales, operations, marketing, managed care, pricing and reimbursement, training and medical affairs. He was also involved in evaluating in-licensing opportunities. Mr. Albers played a key role in the successful US launch of Mozobil® and integrating Campath® and Leukine® into the portfolio (acquired from Bayer in 2009) involving a significant field force restructuring. After the acquisition of Genzyme by Sanofi he represented Genzyme on the US Oncology Integration Team. Prior to Genzyme, he spent five years (2000-2005) as an attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo, where he focused on life sciences transactional work. He has prior experience as a sales representative for Pfizer, Inc. Mr. Albers has a B.Sc. in Marketing from Indiana University, and a law degree (J.D.) and MBA from Georgetown University (Washington, DC).

Andrew Kay, Algeta's President and CEO, said: "Jeff has established a strong track record of commercial leadership and sales success at Genzyme and he brings a broad array of commercial and corporate development experience to Algeta. Working closely with our senior management as part of the executive management team, we are confident his experience and drive will help the establishment of successful commercial operations in the United States, assuming Alpharadin regulatory filing in mid 2012 and subsequent regulatory approval."

Jeff Albers added: "This is a very exciting time to be joining Algeta with Alpharadin advancing through the commercialization phase and its launch, pending approval, within sight. I look forward to working on the Algeta management team and with our partners at Bayer to build a US organization positioned to successfully launch Alpharadin for the treatment of bone metastases in patients with CRPC. In addition I am excited at the prospect of establishing Algeta's alpha-pharmaceutical platform and expanding it into additional indications, with the goal of improving the lives of patients living with these debilitating diseases."

#

For further information, please contact:

Algeta ASA:

Mike Booth
Communications & Corporate Affairs
+47 2202 4510
ir@algeta.com
International media enquiries:

Mark Swallow
Citigate Dewe Rogerson
+44 207 638 9571
mark.swallow@citigatedr.co.uk

US investor enquiries:

Jessica Lloyd
The Trout Group
+1 646 378 2928
jlloyd@troutgroup.com


About Algeta

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.

Algeta's lead product Alpharadin (radium-223 chloride) is a first-in-class, highly targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with advanced forms of cancer and bone metastases. Its localized action helps preserve the surrounding healthy tissue thereby limiting side-effects.

Alpharadin is being developed under a development and commercialization agreement with Bayer Pharma AG. In June 2011, a global phase III clinical trial (ALSYMPCA) of Alpharadin to treat castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases was stopped early after meeting its primary endpoint of significantly improving overall survival. The US Food and Drug Administration (FDA) granted Alpharadin Fast Track designation for this indication. Alpharadin is also in clinical development as a potential new treatment for breast cancer patients with bone metastases, and is in a phase I/IIa trial in combination with docetaxel chemotherapy in CRPC patients with bone metastases.

The development of bone metastases represents a serious development for cancer patients as they are associated with a dramatic decline in patient health and quality of life, ultimately leading to death. Bone metastases represent a major unmet medical need, occurring frequently in certain late-stage cancers, e.g. prostate (in up to 90% patients), breast (up to 80%) and lung (up to 40%).

Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs), which are based on conjugating the alpha-emitter thorium-227 to targeting molecules, as a basis of a future pipeline of tumor-targeting alpha-pharmaceutical candidates.

The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.


Forward-looking Statements

This news release contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. Such forward-looking statements reflect our current views and are based on the information currently available to Algeta. Algeta cannot give any assurance to the correctness of such statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials, collaborations with other companies in the development of targeting molecules and alpha particle payloads, risks associated with technological development, growth management, general economic and business conditions and the pricing environment, the impact of competition, the ability to successfully commercialize Alpharadin and our other products, the risk that research & development will not yield new products that achieve commercial success, manufacturing capacity, the risk of non-approval of patents not yet granted, risks in obtaining regulatory approvals for Alpharadin and our other products and difficulties of obtaining relevant governmental approvals for new products, and the other risks and uncertainties described in our annual report.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

   
Record changed: 2018-02-20

Advertisement

Picture [iito] – Putting Information into Context 600x60px


More documents for Jeffrey W. (Jeff) Albers


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] – Putting Information into Context 600x60px




» top